Diverse Responses of Autoantibodies to the Angiotensin II Type 1 Receptor in Primary Aldosteronism

Williams, Tracy Ann ; Jaquin, Diana ; Burrello, Jacopo ; Philippe, Aurélie ; Yang, Yuhong ; Rank, Petra ; Nirschl, Nina ; Sturm, Lisa ; Hübener, Christoph ; Dragun, Duska ; Bidlingmaier, Martin ; Beuschlein, Felix ; Reincke, Martin

Abstract: Primary aldosteronism is a common form of endocrine hypertension mainly caused by a unilateral aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia (BAH). AT1R-Abs (autoantibodies to the angiotensin II type 1 receptor) have been reported in patients with disorders associated with hypertension. Our objective was to assess AT1R-Ab levels in patients with primary aldosteronism (APA, n=40 and BAH, n=40) relative to patients with primary hypertension (n=40), preeclampsia (n=23), and normotensive individuals (n=25). AT1R-Abs in whole sera were measured using 2 different ELISAs which gave contrasting results. A functional cell-based assay was used to quantify activation of the AT1R (angiotensin II type 1 receptor) using whole sera or affinity-purified antibodies in the absence or presence of losartan (a specific AT1R antagonist). Serum samples from all groups displayed different levels of AT1R activation with different responses to losartan. Patients with BAH displayed higher losartan-independent affinity-isolated agonistic AT1R-Ab levels compared with patients with APA (<0.01) and with normotensive individuals (<0.0001). In patients with APA, BAH, and primary hypertension combined, higher aldosterone-to-renin ratios and lower plasma renin concentrations were associated with higher compared with lower agonistic AT1R-Ab levels. In patients with primary aldosteronism, higher AT1R-Ab activity was associated with an increased likelihood of a diagnosis of BAH compared with APA and with the presence of adrenal hyperplasia detected by computed tomography. Taken together, these data suggest that agonistic AT1R-Abs may have a functional role in a subgroup of patients with primary aldosteronism.

DOI: https://doi.org/10.1161/HYPERTENSIONAHA.119.13156

Diverse Responses of Autoantibodies to the Angiotensin II Type 1 Receptor in Primary Aldosteronism

Tracy Ann Williams, Diana Jaquin, Jacopo Burrello, Aurélie Philippe, Yuhong Yang, Petra Rank, Nina Nirschl, Lisa Sturm, Christoph Hübener, Duska Dragun, Martin Bidlingmaier, Felix Beuschlein, Martin Reincke

See Editorial, pp 745–746

Abstract—Primary aldosteronism is a common form of endocrine hypertension mainly caused by a unilateral aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia (BAH). AT1R-Abs (autoantibodies to the angiotensin II type 1 receptor) have been reported in patients with disorders associated with hypertension. Our objective was to assess AT1R-Ab levels in patients with primary aldosteronism (APA, n=40 and BAH, n=40) relative to patients with primary hypertension (n=40), preeclampsia (n=23), and normotensive individuals (n=25). AT1R-Abs in whole sera were measured using 2 different ELISAs which gave contrasting results. A functional cell-based assay was used to quantify activation of the AT1R (angiotensin II type 1 receptor) using whole sera or affinity-purified antibodies in the absence or presence of losartan (a specific AT1R antagonist). Serum samples from all groups displayed different levels of AT1R activation with different responses to losartan. Patients with BAH displayed higher losartan-independent affinity-isolated agonistic AT1R-Ab levels compared with patients with APA ($P<0.01$) and with normotensive individuals ($P<0.0001$). In patients with APA, BAH, and primary hypertension combined, higher aldosterone-to-renin ratios and lower plasma renin concentrations were associated with higher compared with lower agonistic AT1R-Ab levels. In patients with primary aldosteronism, higher AT1R-Ab activity was associated with an increased likelihood of a diagnosis of BAH compared with APA and with the presence of adrenal hyperplasia detected by computed tomography. Taken together, these data suggest that agonistic AT1R-Abs may have a functional role in a subgroup of patients with primary aldosteronism. **(*Hypertension*. 2019;74:784-792. DOI: 10.1161/HYPERTENSIONAHA.119.13156.)** • **Online Data Supplement**

Key Words: adenoma ■ adrenal hyperplasia ■ aldosterone ■ hypertension ■ preeclampsia ■ adrenal cortex

Primary aldosteronism (PA) is a form of endocrine hypertension caused by the overproduction of aldosterone from one or both adrenal glands (unilateral or bilateral PA, respectively). Unilateral PA is predominantly caused by an aldosterone-producing adenoma (APA) and bilateral forms by bilateral adrenocortical hyperplasia (BAH).[1] APA and BAH mainly arise sporadically, but uncommon familial forms have been described (familial hyperaldosteronism types I-IV).[2,3] Substantial progress has been made in understanding the pathophysiology of familial PA and sporadic APAs with the identification of germline mutations causing 4 familial forms of hyperaldosteronism[4–9] and somatic mutations which drive aldosterone excess in 50% to 80% of APAs.[2,10–12] These advances, however, have not been replicated in understanding the pathogenesis of sporadic BAH. The bilateral nature of the disease led to the proposal of circulating factors, which could trigger bilateral chronic stimulation of the adrenal *zona glomerulosa*.

Graves disease is an established example of an autoimmune disease caused by agonistic autoantibodies which activate the TSHR (thyroid-stimulating hormone receptor) resulting in thyroid hormone production and thyroid cell proliferation.[13–15] In addition to agonistic antibodies, antagonistic and neutral autoantibodies to the TSHR have been described which either block TSH activity or have no apparent effect.[15] Autoimmune responses to other G protein-coupled receptors have been reported in several studies implicating a role for autoantibody activation of the AT1R (angiotensin II type 1 receptor), the α_1-adrenergic and β_1-adrenergic receptors in several cardiovascular disorders.[16–25] Furthermore, multiple studies have reported the detection of AT1R-Abs (autoantibodies

Received April 12, 2019; first decision April 27, 2019; revision accepted June 28, 2019.

From the Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Germany (T.A.W., D.J., Y.Y., P.R., N.N., L.S., M.B., F.B., M.R.); Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Turin, Italy (T.A.W., J.B.); Clinic for Nephrology and Critical Care Medicine, Campus Virchow-Klinikum and Center for Cardiovascular Research, Medical Faculty of the Charité Berlin, Berlin, Germany (A.P., D.D.); Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Germany (C.H.); Berlin Institute of Health, Anna-Luisa-Karsch Str 2 10178 Berlin, Germany (D.D.); Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Switzerland (F.B.).

The online-only Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.119.13156.

Correspondence to Tracy Ann Williams, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, Ziemssenstr. 1, D-80336 München, Germany. Email tracy.williams@med.uni-muenchen.de

to the angiotensin II type 1 receptor) in patients with preeclampsia.[20,26] AT1R-Abs, which recognize the AFHYESQ peptide (position 165–171) in the second extracellular loop of the AT1R, have been implicated as autoantibody-mediated drivers of AT1R agonism. Specifically, ELISAs employing an immobilized synthetic AFHYESQ peptide are often used to assay AT1R-Ab levels.[20,27] Using either ELISA or functional assays, AT1R-Abs have also been reported in patients with PA in whom AT1R-Ab levels are variously reported as higher in patients with APA than with BAH, higher in BAH compared with APA, or similar levels in both subtypes of PA.[28–30] These studies have either used ELISA-based assays, which do not provide information on the agonistic effect of AT1R-Abs, or have included only small cohorts of patients with PA.

Our objective was to establish if functionally active AT1R-Abs are present in a large cohort of 80 patients with PA (40 patients with APA and 40 with BAH) in comparison with primary hypertension (PH, n=40), preeclampsia (n=23), and normotensive individuals (NT, n=25) using 3 assays: 2 different ELISA-based assays both using immobilized full-length AT1R and a highly sensitive cell-based AT1R activation functional assay.

Methods

The data that support the findings of this study are available from the corresponding author on reasonable request.

Patient Samples

For quantification of AT1R-Abs and AT1R activating activity, serum samples from 80 patients with PA (40 with APA and 40 with BAH), 40 with PH, 23 women with preeclampsia, and 25 NT were used. PA was diagnosed in accordance with the Endocrine Society guideline.[31] Patients were screened for PA using the plasma aldosterone-to-direct renin concentration ratio, and diagnosis was confirmed by the intravenous saline load test according to local criteria.[32] All patients with confirmed PA underwent computed tomography (CT) scanning and adrenal venous sampling. The cutoff selectivity index to determine success of catheterization was ≥2 and for the lateralization index to diagnose unilateral PA ≥4.[32] PH was diagnosed in accordance with the European Society Hypertension/cardiology guidelines[33] after ruling out PA, pheochromocytoma and Cushing syndrome. Preeclampsia and Graves disease were diagnosed as described previously.[34,35] Blood sampling for patients with PA and PH was performed at screening for secondary hypertension. Whenever possible, patients were under no treatment or before the beginning of an antihypertensive therapy. When necessary, blood pressure was controlled using the calcium channel blocker verapamil or the α-blocker doxazosin, alone or in combination, in accordance with the ES guideline.[31] Blood samples from patients with Graves disease were withdrawn at the first medical visit and from patients with preeclampsia in the third trimester. All participants gave written informed consent, and the protocol was approved by the local ethics committee.

AT1R Autoantibody Measurements

All AT1R-Abs were measured using 3 different assays. 2 commercially available ELISA kits were used to quantify autoantibodies against the recombinant human full-length AT1R (ELISA-Creative Diagnostics and ELISA-CellTrend).[36,37] The third assay was a cell-based AT1R activation assay (Invitrogen Gene BLAzer beta-lactamase reporter system) to measure agonistic AT1R activity in total serum and in affinity-isolated IgG fractions after preincubation for 1 hour with vehicle or 100 µmol/L losartan. Immunoglobulins were affinity-isolated on protein A/G agarose from 1 mL patient serum, and 1/10 of the affinity-isolated IgGs was used in the functional assay. The isolation of IgGs on protein A/G agarose and their depletion from serum samples was confirmed by Western blotting using a horseradish peroxidase-conjugated goat anti-human antibody (Millipore, 1:50000 dilution; Figure S1 in the online-only Data Supplement).

The cell-based AT1R activation assay employed AT1R-*bla* U2OS cells which stably express the AT1R linked at the C-terminus to the Gal4-VP16 transcription factor via a tobacco etch virus (TEV) protease cleavage site (E-X-X-Y-X-Q-G/S; Invitrogen). The U2OS cells also stably express TEV protease-tagged-β-arrestin/TEV and a β-lactamase reporter gene with Gal4-responsive upstream activator sequences. After AT1R activation, the TEV-protease-β-arrestin is recruited to the AT1R receptor C-terminus and cleaves the TEV cleavage sequence releasing GAL4-VP16 which activates expression of the β-lactamase reporter gene. A Förster resonance energy transfer substrate comprising coumarin and fluorescein fluorophores was used to measure reporter gene activity (ThermoFisher, LiveBLAzer-FRET B/G substrate). In the absence of β-lactamase reporter gene expression, the Förster resonance energy transfer substrate is intact, coumarin excitation transfers fluorescence resonance energy to fluorescein resulting in emission of green fluorescence. When the substrate is cleaved, energy transfer is disrupted, and a blue fluorescence signal is emitted from coumarin excitation. Reporter activities, corresponding to AT1R activation, are given as response ratios which are the ratio of coumarin to fluorescein fluorescence signals (ratio of cleaved to uncleaved substrate) normalized for negative control wells (mock-treated cells).

TSHR Activation Assay

Activity of affinity-isolated IgGs from serum of Graves disease patients was measured using a TSHR agonistic cell-based assay to determine if autoantibody functional activity was maintained after the IgG isolation procedure. The assay uses TSHR ACTOne cells, a HEK-293 CNG (human embryonic kidney-293 cyclic nucleotide-gated) cell line with overexpression of recombinant human TSHR (MyBiosource). The modified CNG channel opens in response to elevated intracellular cAMP levels, and the resultant ion influx and membrane depolarization are measured with a fluorescent membrane potential dye. The assay measures intracellular cAMP levels as a response ratio between TSHR ACTOne cells compared with the parental control cell line (HEK-293 CNG cells).

Adrenal Morphology

CT imaging was used to classify absence or presence of adrenal hyperplasia in adrenals with an abnormal morphology. The absence of hyperplasia group included adrenals with an adenoma, but without hyperplasia, the presence of hyperplasia group included adrenals with hyperplasia alone or hyperplasia and an adenoma. Hyperplasia was defined as mean limb width ≥5 mm.[38] Patients with no adrenal abnormality visible on CT images were excluded from the morphological analysis.

Statistical Analyses

Data were analyzed with the Kolmogorov-Smirnov and Shapiro-Wilk tests to determine distributions. Group differences were calculated for normally distributed data using the ANOVA and post hoc Bonferroni tests. Non-normally distributed data were analyzed using the Kruskal-Wallis test. Accordingly, data are expressed as mean±SD or median (25th to 95th percentile). Categorical variables are presented as absolute numbers, and percentages and differences were analyzed with a χ^2test. Adjusted logistic regression analyses were performed to assess associations of AT1R-Abs and the diagnosis of BAH. IBM SPSS Statistics version 22.0 was used for all analyses.

Results

Clinical Parameters of Patients With PA Versus Primary Hypertension

Groups of patients with APA and BAH had the same age as patients with PH and a similar sex distribution with no significant differences in the proportion of males and females

Table 1. Clinical Parameters of Patients With Primary Aldosteronism and Primary Hypertension

Clinical Parameter	APA (N=40)	BAH (N=40)	PH (N=40)	Overall *P* Value	Pairwise Comparisons		
					APA vs BAH	APA vs PH	BAH vs PH
Age, y	52±10.2	52±9.7	52±19.9	0.964	N.A.	N.A.	N.A.
Sex, ref. male	21 (52.5%)	19 (47.5%)	16 (42.1%)	0.656	N.A.	N.A.	N.A.
BMI, Kg/m^2	27.3±4.1	26.2±5.0	27.4±6.0	0.500	N.A.	N.A.	N.A.
Systolic BP, mm Hg	151±21.5	151±23.8	156±17.2	0.461	N.A.	N.A.	N.A.
Diastolic BP, mm Hg	93±11.0	95±13.6	91±14.6	0.469	N.A.	N.A.	N.A.
PAC, pmol/L	569 [283–1071]	416 [311–583]	225 [128–394]	<0.001	0.742	<0.001	0.002
DRC, mU/L	4.3 [2.0–11.2]	3.4 [2.0–7.3]	18.2 [8.9–45.1]	<0.001	0.831	<0.001	<0.001
ARR_DRC	108 [36–306]	114 [71–162]	16 [6–26]	<0.001	1.000	<0.001	<0.001
Lowest serum K$^+$, mmol/L	2.9 [2.6–3.2]	3.3 [3.0–3.7]	3.9 [3.6–4.2]	<0.001	0.001	<0.001	<0.001

Clinical data of patients with PA (APA or BAH) and PH are presented as average values±SD, absolute numbers with proportions in parenthesis (%) or as medians with lower and upper quartiles in parentheses. *P* values designate the presence of group differences by the ANOVA and Bonferroni post hoc tests (age, BMI, systolic, and diastolic BP), Kruskal–Wallis test (PAC, DRC, ARR_DRC, and potassium), or χ^2 test (sex). Numbers of patient samples in each subgroup are indicated. APA indicates aldosterone-producing adenoma; ARR_DRC, aldosterone-to-renin ratio using direct renin measurements; BAH, bilateral adrenal hyperplasia; BMI, body mass index; BP, blood pressure; DRC, direct renin concentration; PAC, plasma aldosterone concentration; and PH, primary hypertension.

between APA, BAH, and PH groups (47.5%–57.9%). There were no significant between-group differences in systolic or diastolic blood pressure at baseline or in body mass index in patients with APA, BAH, and PH (Table 1). As expected, patients with APA or BAH had higher plasma aldosterone concentrations and lower direct plasma renin concentrations (DRC) at baseline relative to the PH group (plasma aldosterone concentrations: APA group, 569 [283–1071]; BAH, 416 [311–583]; PH 225 [128–394] pmol/L and DRC: APA group, 4.3 [2.0–11.2]; BAH, 3.4 [2.0–7.3]; PH, 18.2 [8.9–45.1] mU/L). Likewise, patients with APA had lower serum potassium concentrations compared with patients with BAH and PH (APA group, 2.9 [2.6–3.2]; BAH, 3.3 [3.0–3.7]; PH 3.9 [3.6–4.2] mmol/L; Table 1).

ELISA Quantification of AT$_1$R-Abs in Different Groups

Autoantibodies recognizing epitopes on the full-length human recombinant AT1R in serum from patients with APA, BAH, PH, preeclampsia, and NT were measured using 2 different ELISAs. Using one approach (ELISA-Creative Diagnostics), patients with preeclampsia displayed significantly higher AT1R-Ab levels compared with all other groups (*P*<0.0001 for all comparisons). The titer of AT1R-Abs was highly similar in the APA and BAH groups (APA group, [0.06–0.21]; BAH, 0.12 [0.06–0.26] ng/mL) with no differences observed compared with either the PH or NT groups (PH group, 0.15 [0.10–0.25]; NT, 0.11 [0.01–0.19] ng/mL; Figure [A]; Table S1). We also used a second ELISA (ELISA-CellTrend) based on AT1R-Ab binding to the full-length AT1R in its native conformation.[36,37] Patients with APA and BAH displayed highly similar levels of AT1R-Abs (APA group, 14.2 [10.4–22.0]; BAH, 14.1 [10.1–19.7] U/mL) which were not significantly different from the PH or NT groups (PH group, 13.5 [10.7–18.7]; NT, 11.4 [10.6–20.8] ng/mL; Figure [B], Table S1). However, AT1R-Ab levels were significantly lower in patients with preeclampsia (8.7 [6.9–11.6] ng/mL) compared with all other groups (*P*<0.05 for all comparisons).

Quantification of AT1R Agonistic Activity in Serum Samples From Different Groups

We tested if serum from the different subgroups of patients and individuals could activate the AT1R in a cell-based functional assay. Treatment of cells with angiotensin II (0–500 pmol/L) demonstrated a dose-dependent effect on AT1R activation which was ablated by preincubation of the cells for 1 hour with the AT1R antagonist losartan (100 µmol/L). The assay measured a specific AT1R functional response to 50 pmol/L angiotensin II which was significantly higher than a corresponding incubation in the presence of losartan (*P*<0.05; Figure S2). Higher AT1R agonistic activity was measured in serum samples from all groups (*P*<0.001 for absence versus presence of losartan for each group). There were no between-group differences for AT1R agonist activity in the absence of losartan. However, in the presence of losartan there were overall differences in the measured functional activation of the AT1R (*P*<0.001) with the BAH group showing higher activity compared with the APA (*P*=0.001), preeclampsia (*P*<0.0001), and NT groups (*P*<0.0001). The PH group also displayed higher levels of functional AT1R-Abs relative to the NT (*P*<0.0001) and the preeclampsia groups (*P*=0.001; Figure [C], Table S1).

Affinity Isolation of IgG Fractions From Different Groups of Serum Samples

To determine if the losartan-independent AT1R activating activity in serum samples was due to IgGs or to other circulating factors, such as angiotensin II, IgGs were affinity-isolated from all serum samples on protein A/G-agarose to assess AT1R agonist activity in the cell-based AT1R functional assay (Figure S1 and S2). We first tested if the IgG affinity isolation procedure produced functionally active autoantibodies. For this, IgGs were isolated from the serum of patients with Graves disease (N=9) and measured TSHR activation using a cell-based functional assay. Using IgG fractions isolated from patients with Graves disease, comparison of TSHR activation in the ACT-ONE cell line (with stable overexpression of the



Figure. Measurement of AT1R (angiotensin II type 1 receptor) autoantibodies and AT1R activating response in patients with primary aldosteronism, primary hypertension, preeclampsia, and in normotensive individuals. Scatter dot plots showing quantification of AT1R-Abs in total serum of patients with primary aldosteronism (PA; aldosterone-producing adenoma [APA] and bilateral adrenal hyperplasia [BAH]), primary hypertension (PH), preeclampsia (PE), and normotensive individuals by measurements using ELISA-Creative Diagnostics (**A**) or ELISA-CellTrend (**B**). A cell-based AT1R activation assay was used to measure AT1R-Ab agonist activity in total serum (**C**) or in agarose-A/G affinity-isolated IgG fractions (**D**) in the absence (light gray points) or presence (dark gray points) of 100 μm losartan as indicated. **D**, also highlights the agonistic AT1R-Ab levels in patients with adrenal hyperplasia at computed tomographic imaging (red points). The response ratio represents AT1R activation of β-lactamase activity measured as coumarin to fluorescein fluorescence (cleaved to uncleaved substrate ratio) normalized for negative controls. Horizontal lines within boxes indicate the median, and the lower and upper horizontal lines indicate the 95% CI. *P* values were calculated using the Kruskal-Wallis test and indicate **** difference ($P<0.0001$) from NT (**A**); *difference ($P<0.05$) from normotensive individuals (NT, **B**); ***difference ($P<0.001$) absence vs presence of losartan for each subgroup; $^{\$}$difference ($P<0.01$) from BAH; $^{\#\#\#\#}$difference ($P<0.0001$) from NT (presence of losartan); $^{++++}$difference ($P<0.0001$) from PE (presence of losartan); $^{++}$difference ($P<0.01$) from PE (presence of losartan); (**C**); **difference ($P<0.01$) from NT (absence of losartan), ****difference ($P<0.0001$) from NT (absence of losartan); $^{\$}$difference ($P<0.01$; presence of losartan); $^{\#\#\#\#}$difference ($P<0.0001$) from NT (presence of losartan); $^{\#\#}$difference ($P<0.01$) from NT (presence of losartan); $^{\#}$difference ($P<0.05$) from NT (presence of losartan); (**D**). Numbers of patient samples in each subgroup were APA, $N=40$; BAH, $N=40$; PH, $N=40$; PE, $N=23$; and NT, $N=25$.

human TSHR) with the parental cell line (without expression of recombinant human TSHR) demonstrated that 6 of the 9 IgG fractions displayed TSHR agonistic activity (Figure S3). The remaining 3 IgG fractions exhibited no significant TSHR activation indicating neutral or blocking activity to the TSHR (Figure S3). Overall, the approach used for the affinity isolation of autoantibodies from patients with Graves disease maintained TSHR agonist functional activity, thereby validating the method used for the isolation of IgG fractions.

Quantification of AT1R Agonistic Activity in Affinity-Isolated IgG Fractions From Different Groups

There were group differences in the cell-based assay response (overall difference $P<0.001$) using affinity-isolated IgGs. The BAH, PH, and preeclampsia groups displayed higher levels of AT1R activating autoantibodies compared with the NT group ($P<0.0001$, $P=0.007$, and $P<0.0001$, respectively), and the BAH group had higher functional AT1R-Ab levels than the APA group ($P=0.01$). The agonistic AT1R-Ab levels were not abolished in the presence of losartan, and significant group differences were observed (Table S1). Higher losartan-independent AT1R functional activity was measured with IgGs isolated from patients with BAH, PH, and preeclampsia compared with the NT group ($P<0.0001$, $P=0.006$, and $P=0.016$, respectively) and in the BAH versus APA groups ($P=0.01$; Figure [D], Table S1). Comparison of AT1R activation in the cell assay with the functional response obtained with angiotensin II in the dose-response assay indicated that the median AT1R activation achieved with affinity-isolated antibodies from patients with BAH in the presence or absence of losartan was equivalent to 50 to 100 pmol/L angiotensin II (Figure S2 and Table S1).

Clinical Parameters of Patients According to Functional AT1R-Ab Levels

Affinity-purified agonistic AT1R-Ab levels were categorized into higher and lower AT1R-Ab levels according to the median AT1R-Ab activity in the cell-based assay for patients with APA, BAH, and PH combined. In this cohort, in the absence of losartan, patients with BAH had higher AT1R-Ab levels (BAH represented 41.2% of 68 patients of the combined cohort with higher AT1R-Ab levels compared with 23.1% of 52 patients with lower AT1R-Ab levels, $P=0.037$; Table 2). Patients with APA had lower AT1R-Ab levels (APA represented 23.5% of 68 patients of the combined cohort with higher AT1R-Ab levels compared with 46.2% of 52 patients

Table 2. Clinical Parameters of Patients With Primary Aldosteronism and Primary Hypertension According to Functional AT1R-Ab Levels

Clinical Parameter	AT1R-Ab Level Minus Losartan		*P* Value	AT1R-Ab Level Plus Losartan		*P* Value
	<Median	≥Median		<Median	≥Median	
Diagnosis						
APA	24 (46.2)	16 (23.5)	0.009	23 (40.4)	17 (27.0)	0.120
BAH	12 (23.1)	28 (41.2)	0.037	14 (24.6)	26 (41.3)	0.053
PH	16 (30.7)	24 (35.3)	0.603	20 (35.1)	20 (31.7)	0.699
Age, y	54±14.8	55±16.6	0.749	54±15.5	55±16.2	0.851
Sex, ref. male	30 (57.7)	39 (57.4)	0.970	28 (49.1)	41 (65.1)	0.077
BMI, Kg/m^2	28.2±4.7	27.5±5.0	0.431	27.2±4.2	28.4±5.3	0.177
Systolic BP, mm Hg	151±23.9	147±19.2	0.376	148±25.1	149±17.4	0.709
Diastolic BP, mm Hg	92±15.0	86±12.5	0.018	89±16.9	89±10.7	0.854
PAC, pmol/L	235 [150–553]	300 [167–556]	0.499	236 [130–550]	286 [186–569]	0.338
DRC, mU/L	11.7 [5.7–31.8]	5.7 [2.2–27.0]	0.011	11.9 [5.3–39.7]	5.6 [2.3–16.3]	0.003
ARR_DRC	23 [10–55]	47 [13–139]	0.029	19 [7–60]	49 [16–137]	0.003
Lowest serum K$^+$, mmol/L	3.2 [2.9–3.9]	3.4 [3.2–3.9]	0.333	3.3 [2.9–3.9]	3.4 [3.2–3.9]	0.084

Clinical parameters of the combined cohort of patients with APA, BAH, and PH were analyzed according to AT1R-Ab levels (affinity-purified autoantibody activity measured with the cell-based assay) categorized according to the median value of the combined cohort (median values, 0.27 and 0.28 in the absence and presence of losartan respectively). Data are presented as average values±SD, absolute numbers with proportions in parenthesis (%), or as medians with lower and upper quartiles in parentheses. *P* values designate the presence of group differences by the ANOVA and Bonferroni post hoc tests (age, BMI, systolic, and diastolic BP), Kruskal–Wallis test (PAC, DRC, ARR_DRC, and potassium), or χ^2 test (sex, diagnosis). Numbers of patient samples in each subgroup are indicated. APA indicates aldosterone-producing adenoma; ARR_DRC, aldosterone-to-renin ratio using direct renin measurements; BAH, bilateral adrenal hyperplasia; BMI, body mass index; BP, blood pressure; DRC, direct renin concentration; PAC, plasma aldosterone concentration; and PH, primary hypertension.

with lower AT1R-Ab levels, *P*=0.009; Table 2). Although functional AT1R-Ab levels were similar in the BAH versus PH groups (Figure [D]; Table S1), patients with PH with lower versus higher AT1R-Ab levels were similarly distributed in the combined cohort (APA+BAH+PH). The PH group with lower AT1R-Ab levels comprised 30.7% of 52 patients of the combined cohort compared with 35.3% of 68 patients with higher levels (*P*=0.603; Table 2).

In the APA, BAH, and PH combined cohort, higher levels of agonistic AT1R-Abs were also associated with a higher aldosterone-to-renin ratio (ARR_DRC) and a lower DRC in the absence of losartan (DRC: 5.7 mU/mL [2.2–27.0] versus 11.7 mU/mL [5.7–31.8], *P*=0.011; ARR_DRC: 47 [13–139] versus 23 [10–55], *P*=0.029, for higher versus lower AT1R-Ab levels, respectively), and these differences were maintained in the presence of losartan (Table 2).

Patients with PA with higher agonistic AT1R-Ab levels, in the absence of losartan, had an increased likelihood of a diagnosis of BAH versus APA after adjustment for confounding effects of age, systolic BP, plasma aldosterone concentrations, or DRC (Table 3). Higher losartan-independent agonistic AT1R-Ab levels were not associated with a diagnosis of BAH compared with APA after correction for systolic BP and plasma aldosterone concentrations. There was no association of higher AT1R-Ab levels with a diagnosis of BAH compared with PH in either the absence of presence of losartan (Table 3).

Adrenal Morphology According to Functional AT1R-Ab Levels

Adrenal abnormalities were absent on CT images in 3 patients diagnosed with APA and in 17 patients diagnosed with BAH, and these cases were excluded from the morphological analysis. Higher affinity-purified AT1R-Ab levels in the absence of losartan were associated with the presence of adrenal hyperplasia, when AT1R-Ab levels were treated as either a continuous variable (AT1R activating activity response ratio, 0.3 [0.26–0.39] versus 0.26 [0.23–0.29] in the presence and absence of hyperplasia, respectively, *P*=0.011) or categorized as higher or lower according to the median AT1R-Ab level (76.0 % of 25 patients with adrenal hyperplasia had higher AT1R-Ab levels compared with 37.1% of 35 patients without adrenal hyperplasia, *P*=0.003; Table 4). In the presence of losartan, AT1R-Ab activities were similar in the presence versus absence of hyperplasia groups (Table 4).

The distribution of individual patients with PA (APA and BAH) with adrenal hyperplasia according to AT1R-Ab activating activity is shown in Figure [D]. In patients with PA, 83.3% of 12 and 69.2% of 13 patients of patients classified with adrenal hyperplasia in the APA and BAH groups, respectively, had AT1R-Ab levels above or equal to the median value for their group in the absence of losartan (Figure [D]).

Discussion

Autoantibodies that potentially elicit a functional response by binding to G protein-coupled receptors have been described in several cardiovascular disorders.[25] Many studies have reported AT1R-Ab binding to an epitope in the second extracellular loop (AFHYESQ) of the AT1R in different groups of patients.[20] The best characterized is AT1R-Abs in preeclampsia where a functional role has been implicated using cardiomyocyte contraction assays in which assay response was ablated either by the AT1R antagonist losartan or with

Table 3. Association of Agonistic Affinity-Purified AT1R-Ab Levels and Diagnosis of BAH

	BAH vs APA		BAH vs PH	
Clinical Parameter	OR (CI 95%)	*P* Value	OR (CI 95%)	*P* Value
Agonistic AT1R-Ab level–losartan				
AT1R-Abs, ref. ≥median	3.425 (1.342–8.696)	0.010	1.515 (0.589–3.891)	0.388
Age, y	0.976 (0.941–1.012)	0.186	1.025 (0.997–1.053)	0.078
AT1R-Abs, ref. ≥median	3.663 (1.420–9.434)	0.007	1.495 (0.587–8.817)	0.339
Systolic BP, mm Hg	1.019 (0.005–1.044)	0.116	0.993 (0.972–1.015)	0.532
AT1R-Abs, ref. ≥median	3.521 (1.361–9.091)	0.009	1.887 (0.688–5.319)	0.231
PAC, pmol/L	1.001 (1.000–1.003)	0.072	1.003 (1.001–1.005)	0.003
AT1R-Abs, ref. ≥median	3.546 (1.395–9.009)	0.008	1.603 (0.630–4.065)	0.322
DRC, mU/L	0.996 (0.989–1.004)	0.298	0.996 (0.990–1.002)	0.221
Agonistic AT1R-Ab Level+Losartan				
AT1R-Abs, ref. ≥median	2.571 (1.027–6.452)	0.044	1.980 (0.786–5.000)	0.147
Age, y	0.973 (0.938–1.009)	0.135	1.026 (0.999–1.055)	0.062
AT1R-Abs, ref. ≥median	2.358 (0.943–5.882)	0.066	1.832 (0.745–4.505)	0.187
Systolic BP, mm Hg	1.015 (0.992–1.039)	0.211	0.993 (0.971–1.014)	0.497
AT1R-Abs, ref. ≥median	2.381 (0.947–5.988)	0.065	2.278 (0.838–6.211)	0.107
PAC, pmol/L	1.001 (1.000–1.002)	0.086	1.003 (1.001–1.005)	0.003
AT1R activation, ref. ≥median	2.500 (1.007–6.211)	0.048	1.698 (0.678–4.255)	0.258
DRC, mU/L	0.966 (0.989–1.004)	0.323	0.997 (0.990–1.003)	0.314

Logistic regression analyses were performed to determine the potential association of agonistic autoantibody levels with a diagnosis of BAH with adjustment for confounding effects of a single clinical variable per level (age, systolic BP, PAC, or DRC) in the absence and presence of losartan. Autoantibody levels were categorized according to the median affinity-purified AT1R-Ab level in the cell-based assay as shown. Data are presented as OR with 95% CI. An OR >1 indicates an increased likelihood for a diagnosis of BAH in the presence of agonistic AT1R-Ab activity ≥ median value independent of the tested confounding variable (age, systolic BP, PAC, and DRC). APA indicates aldosterone-producing adenoma; AT1R, angiotensin II type 1 receptor; BAH, bilateral adrenal hyperplasia; BP, blood pressure; DRC, direct renin concentration; OR, odds ratio; PAC, plasma aldosterone concentration; and PH, primary hypertension.

the AFHYESQ peptide.[20,39] The prevalence of AT1R-Abs in preeclampsia varies widely with reports employing an ELISA ranging from 48% of 58 patients[40] to 100% of 25 patients.[20] However, targeting the AFHYESQ peptide in ELISA assays has limitations because binding to linear immobilized peptides may not correlate with AT1R agonism and binding to conformational epitopes cannot be assessed.[41] A commercially available ELISA (ELISA-CellTrend), routinely used in solid organ transplantation, has been developed based on autoantibody binding to the full-length AT1R in the native conformation.[37] Using this conformation sensitive assay, we demonstrated highly contrasting low AT1R-Ab levels compared with a different ELISA method which appears to greatly overestimate the level of AT1R-Abs in patients with preeclampsia.

The pathophysiology of sporadic BAH is poorly understood. Advances in knowledge are hampered by the highly limited availability of tissue samples for molecular studies because patients with BAH are not usually surgically treated. Despite this, recent studies have suggested a role for adrenocortical hyperplasia in patients with bilateral but asymmetrical inappropriate aldosterone production[42] or a role for small clusters of cells located beneath the adrenal capsule with high aldosterone synthase expression (called aldosterone-producing cell clusters) in surgically treated patients diagnosed with bilateral PA.[43] Thus, BAH may not be a distinct entity but a disorder comprising clinical and biochemical variability arising from morphological heterogeneity representing the variable response of the adrenal cortex to circulating, environmental, and genetic factors.

A role for autoantibodies that trigger bilateral chronic stimulation of the adrenal *zona glomerulosa* via activation of the AT1R has been proposed,[44] but a pathogenic role for AT1R-Abs in PA remains unclear because of conflicting reports that used different methods for assessment of antibody levels.[28–30] One study found a 2-fold increase of AT1R-Abs against the AFHYESQ peptide in an ELISA in patients with APA (n=26) compared with patients with BAH (n=20) and proposed the use of this assay as a potential diagnostic tool to differentiate the 2 different types of PA.[28] Using a similar ELISA-based AFHYESQ assay, no difference in AT1R-Ab levels were observed in 44 patients with PA (15 with APA and 29 with BAH) compared with 18 normotensive individuals (n=18) and no difference in AT1R-Ab levels between the patients with APA and BAH.[30] However, measuring antibody binding to the linear AFHYESQ peptide in ELISA assays, as used in many studies, does not necessarily correlate with AT1R agonism.

To address the agonistic activity of AT1R-Abs in PA, Kem et al[29] reported increased AT1R-Ab levels in patients

Table 4. Functional AT1R Autoantibody Levels Stratified by Adrenal Morphology

Clinical Parameter	Hyperplasia		*P* Value
	Absence (n=35)	Presence (n=25)	
Diagnosis			0.066
APA	25 (71.4)	12 (48.0)	
BAH	10 (28.6)	13 (52.0)	
Agonistic AT1R-Ab level–losartan			
AT1R-Abs (response ratio)	0.26 [0.23–0.29]	0.30 [0.26–0.39]	0.011
AT1R-Abs (ref. ≥median)	13 (37.1)	19 (76.0)	0.003
Agonistic AT1R-Ab level+losartan			
AT1R-Abs (response ratio)	0.27 [0.20–0.30]	0.30 [0.24–0.36]	0.149
AT1R-Abs (ref. ≥median)	16 (45.7)	15 (60.0)	0.205

Adrenal morphology of patients with PA was determined from CT results to classify absence or presence of hyperplasia in adrenals with morphological abnormalities. Numbers of patient samples in each subgroup are indicated. Affinity-purified agonistic AT1R-Ab levels, measured with the cell-based assay, were treated as continuous variables and presented as medians with lower and upper quartiles in parenthesis or categorized as higher and lower agonistic AT1R-Ab levels according to the median value for patients with APA and BAH combined and presented as absolute numbers with proportions in parenthesis. *P* values designate the presence of group differences by the Kruskal–Wallis test (AT1R-Ab levels), or χ^2 test (diagnosis, AT1R-Ab levels after categorization). APA indicates aldosterone-producing adenoma; AT1R, angiotensin II type 1 receptor; BAH, bilateral adrenal hyperplasia; CT, computed tomography; and PA, primary aldosteronism.

with PA (n=13) compared with control subjects (n=20) using cell-based assays to measure a functional response in AT1R-transfected cells and reported the contractile effects of the isolated IgGs in perfused rat cremaster arterioles. In contrast to other reports, an increased prevalence of AT1R-Abs in patients with BAH relative to patients with APA was reported.[29] However, the number of patients with PA assessed for AT1R-Ab levels was small, the stimulating activity of low potency and the affinity-isolated antibodies did not elicit a dose-dependent functional effect.[29]

The diverse observations for the prevalence and potential role of AT1R-Abs and the limited understanding of the pathogenesis of bilateral PA highlight the need for studies to measure autoantibodies using robust functional assays in large and well-characterized cohorts of patients with PA. Herein, we assessed AT1R-Ab levels in a cohort of 80 patients with PA diagnosed in accordance with rigorous criteria and with subtype diagnosis (APA versus BAH) defined by adrenal venous sampling. After this approach, ELISA-based measurements using the immobilized full-length AT1R gave contrasting results for AT1R-Ab levels in patients with preeclampsia and did not reveal statistical differences between patients with BAH or APA compared with PH or NT. We, hence, also used a cell-based AT1R functional assay which exploits specific activation of the β-lactamase reporter gene on ligand binding to the AT1R. With this assay, similar levels of AT1R activation were measured in whole serum from all groups. However, between-group differences were shown using affinity-isolated IgGs which demonstrated significantly higher levels of agonistic AT1R-Abs in patients with BAH compared with APA and in patients with BAH, PH, and preeclampsia relative to the NT group both in the presence and absence of losartan.

These activities implicate the existence of an alternative epitope structurally remote from losartan binding sites. AT1R is increasingly recognized as a multi-ligand binding surface and epitopes discovered in solid organ transplant patients are not identical with those in patients with preeclampsia.[37] Some reports suggest that, in addition to classical G protein-mediated signaling, biased AT1R signaling mediated by β-arrestin[45,46] may play a role in aldosterone production and have pathological implications for the progression to heart failure after myocardial infarction.[47,48] Because losartan antagonizes G protein signaling but is ineffective in ablating β-arrestin-mediated signaling,[47,48] the losartan-independent activity we report presumably comprises biased AT1R signaling.

We also demonstrate that higher agonistic AT1R-Ab levels are associated with clinical parameters characteristic of autonomous aldosterone production in PA, such as higher aldosterone-to-renin ratios and lower plasma renin levels. The degree of functional activity of AT1R-Abs in this study appears low but is potentially pathologically relevant because the median AT1R-Ab agonistic activity in patients with BAH corresponds to greater than that achieved with 50 pmol/L angiotensin II, a concentration similar to plasma angiotensin II concentrations reported in patients with chronic kidney disease and considerably higher than in healthy individuals.[49]

A potential pathogenic role of agonistic AT1R-Abs in PA is suggested by the association of higher active AT1R-Ab levels—in the absence but not in the presence of losartan—with an increased likelihood of a diagnosis of BAH compared with APA and with an increased incidence of adrenal hyperplasia. Adrenals harboring an APA also often display hyperplasia of the zona glomerulosa adjacent to the adenoma.[42,50] It is notable that within the group of patients with APA, those with evidence of hyperplasia at CT scanning tend to display higher levels of AT1R-Ab agonistic activity compared with patients with APA without hyperplasia. The imaging data should, however, be treated with caution considering the potential for incorrect classification of an adenoma versus hyperplasia.

Taken together the present data indicate that AT1R-Abs may play a role in patients with BAH which could feasibly exacerbate the effects of additional pathophysiological factors, such as aldosterone-producing cell clusters which have been reported as larger, more numerous and with a higher prevalence of aldosterone-driver mutations than normal adrenals.[43] Notwithstanding the observations reported herein, the possibility that AT1R-Abs are a marker of hypertension rather than having a pathogenic role cannot be excluded.

In conclusion, some patients with disorders related to hypertension have activating autoantibodies to the AT1R. Some AT1R-Abs function via a mechanism diverse from the classical G protein-mediated AT1R signaling and implicate a role for losartan-independent biased AT1R signaling. Overall, the present study suggests a role for agonistic autoantibodies to the AT1R in a subgroup of patients with PA, comprising those patients with adrenal hyperplasia.

Perspectives

A role for AT1R-Abs has been implicated in several cardiovascular disorders, but evidence for a direct function in disease pathophysiology is lacking. In vivo, experiments in mice subjected to infusion of AT1R-Abs from patients with PA could clarify the impact of AT1R-Abs on aldosterone production. A longitudinal analysis is planned to measure the response of AT1R-Ab levels to adrenal surgery or mineralocorticoid receptor antagonism in patients with PA with long-term follow-up. Epitope mapping using synthetic peptides to competitively abolish autoantibody-mediated AT1R activation will aid the identification of AT1R-Ab binding sites and establish any role for autoantibodies in biased signaling.

Sources of Funding

This work was supported by the European Research Council under the European Union's Horizon 2020 research and innovation program (grant agreement No [694913] to M. Reincke) and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Projektnummer: 314061271-TRR 205 to F. Beuschlein, M. Reincke, T.A. Williams; and by DFG grants BE 2177/13-1 and BE 2177/18-1 to F. Beuschlein and RE 752/20–1 to M. Reincke. This work was also supported by the Else Kröner-Fresenius Stiftung in support of the German Conns Registry-Else-Kröner Hyperaldosteronism Registry (2013_A182 and 2015_A171 to M Reincke) and from a grant from the Ministero dell´Istruzione, dell´Universita e della Ricerca (MIUR, ex-60% 2015–2016 to T.A. Williams).

Disclosures

None.

References

1. Stowasser M, Gordon RD. Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney. *Physiol Rev*. 2016;96:1327–1384. doi: 10.1152/physrev.00026.2015
2. Prada ETA, Burrello J, Reincke M, Williams TA. Old and new concepts in the molecular pathogenesis of primary aldosteronism. *Hypertension*. 2017;70:875–881. doi: 10.1161/HYPERTENSIONAHA.117.10111
3. Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. *J Intern Med*. 2019;285:126–148. doi: 10.1111/joim.12831
4. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. *Nature*. 1992;355:262–265. doi: 10.1038/355262a0
5. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. *Science*. 2011;331:768–772. doi: 10.1126/science.1198785
6. Scholl UI, Stölting G, Nelson-Williams C, et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. *Elife*. 2015;4:e06315. doi: 10.7554/eLife.06315
7. Scholl UI, Stölting G, Schewe J, et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. *Nat Genet*. 2018;50:349–354. doi: 10.1038/s41588-018-0048-5
8. Fernandes-Rosa FL, Daniil G, Orozco IJ, Göppner C, El Zein R, Jain V, Boulkroun S, Jeunemaitre X, Amar L, Lefebvre H, Schwarzmayr T, Strom TM, Jentsch TJ, Zennaro MC. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. *Nat Genet*. 2018;50:355–361. doi: 10.1038/s41588-018-0053-8
9. Perez-Rivas LG, Williams TA, Reincke M. Inherited forms of primary hyperaldosteronism: new genes, new phenotypes and proposition of a new classification. *Exp Clin Endocrinol Diabetes*. 2019;127:93–99. doi: 10.1055/a-0713-0629
10. Williams TA, Monticone S, Schack VR, et al. Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. *Hypertension*. 2014;63:188–195. doi: 10.1161/HYPERTENSIONAHA.113.01733
11. Fernandes-Rosa FL, Williams TA, Riester A, et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. *Hypertension*. 2014;64:354–361. doi: 10.1161/HYPERTENSIONAHA.114.03419
12. Lenzini L, Rossitto G, Maiolino G, Letizia C, Funder JW, Rossi GP. A meta-analysis of somatic KCNJ5 K(+) channel mutations in 1636 patients with an aldosterone-producing adenoma. *J Clin Endocrinol Metab*. 2015;100:E1089–E1095. doi: 10.1210/jc.2015-2149
13. Adams DD, Fastier FN, Howie JB, Kennedy TH, Kilpatrick JA, Stewart RD. Stimulation of the human thyroid by infusions of plasma containing LATS protector. *J Clin Endocrinol Metab*. 1974;39:826–832. doi: 10.1210/jcem-39-5-826
14. Davies TF, Ando T, Lin RY, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to graves disease. *J Clin Invest*. 2005;115:1972–1983. doi: 10.1172/JCI26031
15. Morshed SA, Davies TF. Graves' disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies. *Horm Metab Res*. 2015;47:727–734. doi: 10.1055/s-0035-1559633
16. Wallukat G, Wollenberger A. Effects of the serum gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic beta adrenoceptor function in cultured neonatal rat heart myocytes. *Biomed Biochim Acta*. 1987;46:S634–S639.
17. Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. *Circ Res*. 1989;64:97–103. doi: 10.1161/01.res.64.1.97
18. Fu ML, Herlitz H, Wallukat G, Hilme E, Hedner T, Hoebeke J, Hjalmarson A. Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension. *Lancet*. 1994;344:1660–1663. doi: 10.1016/s0140-6736(94)90456-1
19. Luther HP, Homuth V, Wallukat G. Alpha 1-adrenergic receptor antibodies in patients with primary hypertension. *Hypertension*. 1997;29:678–682. doi: 10.1161/01.hyp.29.2.678
20. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. *J Clin Invest*. 1999;103:945–952. doi: 10.1172/JCI4106
21. Wenzel K, Haase H, Wallukat G, et al. Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension. *PLoS One*. 2008;3:e3742. doi: 10.1371/journal.pone.0003742
22. Dragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. *N Engl J Med*. 2005;352:558–569. doi: 10.1056/NEJMoa035717
23. Dragun D. Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation. *Transplantation*. 2008;86:1019–1025. doi: 10.1097/TP.0b013e3181889748
24. Dragun D, Philippe A. From mother to child–transplacental effect of AT1R-AA in preeclampsia. *Nephrol Dial Transplant*. 2010;25:1774–1776. doi: 10.1093/ndt/gfq167
25. Luft FC. Activating autoantibodies and cardiovascular disease. *Physiology (Bethesda)*. 2013;28:254–261. doi: 10.1152/physiol.00014.2013
26. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. *Hypertension*. 2010;55:386–393. doi: 10.1161/HYPERTENSIONAHA.109.140061
27. Wenzel K, Rajakumar A, Haase H, et al. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. *Hypertension*. 2011;58:77–84. doi: 10.1161/HYPERTENSIONAHA.111.171348
28. Rossitto G, Regolisti G, Rossi E, Negro A, Nicoli D, Casali B, Toniato A, Caroccia B, Seccia TM, Walther T, Rossi GP. Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma. *Hypertension*. 2013;61:526–533. doi: 10.1161/HYPERTENSIONAHA.112.202945
29. Kem DC, Li H, Velarde-Miranda C, Liles C, Vanderlinde-Wood M, Galloway A, Khan M, Zillner C, Benbrook A, Rao V, Gomez-Sanchez CE, Cunningham MW, Yu X. Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism. *J Clin Endocrinol Metab*. 2014;99:1790–1797. doi: 10.1210/jc.2013-3282
30. Sabbadin C, Ceccato F, Ragazzi E, Boscaro M, Betterle C, Armanini D. Evaluation of angiotensin II type-1 receptor antibodies in primary aldosteronism and further considerations about their possible pathogenetic role. *J Clin Hypertens (Greenwich)*. 2018;20:1313–1318. doi: 10.1111/jch.13351
31. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical

practice guideline. *J Clin Endocrinol Metab*. 2016;101:1889–1916. doi: 10.1210/jc.2015-4061
32. Williams TA, Reincke M. Management of endocrine disease: diagnosis and management of primary aldosteronism: the Endocrine Society Guideline 2016 revisited. *Eur J Endocrinol*. 2018;179:R19–R29. doi: 10.1530/EJE-17–0990
33. Williams B, Mancia G, Spiering W, et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39:3021–3104. doi: 10.1093/eurheartj/ehy339
34. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, Zeeman GG, Brown MA. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. *Pregnancy Hypertens*. 2014;4:97–104. doi: 10.1016/j.preghy.2014.02.001
35. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of graves' hyperthyroidism. *Eur Thyroid J*. 2018;7:167–186. doi: 10.1159/000490384
36. Philogene MC, Bagnasco S, Kraus ES, Montgomery RA, Dragun D, Leffell MS, Zachary AA, Jackson AM. Anti-Angiotensin II type 1 receptor and anti-endothelial cell antibodies: a cross-sectional analysis of pathological findings in allograft biopsies. *Transplantation*. 2017;101:608–615. doi: 10.1097/TP.0000000000001231
37. Dragun D, Catar R, Philippe A. Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity. *Kidney Int*. 2016;90:280–288. doi: 10.1016/j.kint.2016.03.019
38. Lingam RK, Sohaib SA, Vlahos I, Rockall AG, Isidori AM, Monson JP, Grossman A, Reznek RH. CT of primary hyperaldosteronism (Conn's syndrome): the value of measuring the adrenal gland. *AJR Am J Roentgenol*. 2003;181:843–849. doi: 10.2214/ajr.181.3.1810843
39. Rieber-Mohn AB, Sugulle M, Wallukat G, Alnæs-Katjavivi P, Leite Størvold G, Bolstad N, Redman CW, Dechend R, Staff AC. Auto-antibodies against the angiotensin II type I receptor in women with uteroplacental acute atherosis and preeclampsia at delivery and several years postpartum. *J Reprod Immunol*. 2018;128:23–29. doi: 10.1016/j.jri.2018.05.008
40. Zhang S, Zheng R, Yang L, Zhang X, Zuo L, Yang X, Bai K, Song L, Tian J, Yang J, Liu H. Angiotensin type 1 receptor autoantibody from preeclamptic patients induces human fetoplacental vasoconstriction. *J Cell Physiol*. 2013;228:142–148. doi: 10.1002/jcp.24113
41. Jahns R, Boege F. Questionable validity of peptide-based ELISA strategies in the diagnostics of cardiopathogenic autoantibodies that activate G-protein-coupled receptors. *Cardiology*. 2015;131:149–150. doi: 10.1159/000376546
42. Meyer LS, Wang X, Sušnik E, et al. Immunohistopathology and steroid profiles associated with biochemical outcomes after adrenalectomy for unilateral primary aldosteronism. *Hypertension*. 2018;72:650–657. doi: 10.1161/HYPERTENSIONAHA.118.11465
43. Omata K, Satoh F, Morimoto R, Ito S, Yamazaki Y, Nakamura Y, Anand SK, Guo Z, Stowasser M, Sasano H, Tomlins SA, Rainey WE. Cellular and genetic causes of idiopathic hyperaldosteronism. *Hypertension*. 2018;72:874–880. doi: 10.1161/HYPERTENSIONAHA.118.11086
44. Williams TA, Mulatero P, Bidlingmaier M, Beuschlein F, Reincke M. Genetic and potential autoimmune triggers of primary aldosteronism. *Hypertension*. 2015;66:248–253. doi: 10.1161/HYPERTENSIONAHA.115.05643
45. Maning J, Negussie S, Clark MA, Lymperopoulos A. Biased agonism/antagonism at the AngII-AT1 receptor: implications for adrenal aldosterone production and cardiovascular therapy. *Pharmacol Res*. 2017;125(pt A):14–20. doi: 10.1016/j.phrs.2017.05.009
46. Cahill TJ III, Thomsen AR, Tarrasch JT, et al. Distinct conformations of GPCR-β-arrestin complexes mediate desensitization, signaling, and endocytosis. *Proc Natl Acad Sci USA*. 2017;114:2562–2567. doi: 10.1073/pnas.1701529114
47. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Koch WJ. Adrenal beta-arrestin 1 inhibition *in vivo* attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. *J Am Coll Cardiol*. 2011;57:356–365. doi: 10.1016/j.jacc.2010.08.635
48. Valero TR, Sturchler E, Jafferjee M, Rengo G, Magafa V, Cordopatis P, McDonald P, Koch WJ, Lymperopoulos A. Structure-activity relationship study of angiotensin II analogs in terms of β-arrestin-dependent signaling to aldosterone production. *Pharmacol Res Perspect*. 2016;4:e00226. doi: 10.1002/prp2.226
49. Schulz A, Jankowski J, Zidek W, Jankowski V. Absolute quantification of endogenous angiotensin II levels in human plasma using ESI-LC-MS/MS. *Clin Proteomics*. 2014;11:37. doi: 10.1186/1559-0275-11-37
50. Gomez-Sanchez CE, Kuppusamy M, Reincke M, Williams TA. Disordered CYP11B2 expression in primary aldosteronism. *Horm Metab Res*. 2017;49:957–962. doi: 10.1055/s-0043-122238

Novelty and Significance

What Is New?

- AT1R-Ab (autoantibodies to the angiotensin II type 1 receptor) levels were measured in groups of patients with hypertension compared with normotensive individuals.
- Higher agonistic AT1R-Abs levels were present in bilateral primary aldosteronism, primary hypertension, and preeclampsia groups compared with normotensive individuals.
- Patients with bilateral versus unilateral primary aldosteronism had higher levels of agonistic AT1R-Abs.

What Is Relevant?

- AT1R-Abs measured by ELISA did not correlate with functional activation of the AT1R.
- Patients with higher AT1R-Ab activity levels have an increased likelihood of a diagnosis of bilateral than unilateral primary aldosteronism.
- Higher levels of agonistic AT1R-Abs were associated with higher aldosterone-to-renin ratios and lower plasma renin concentrations.
- Patients with primary aldosteronism with adrenal hyperplasia displayed higher agonistic AT1R-Abs levels.

Summary

Agonistic autoantibodies to the AT1R are present in patients with disorders related to hypertension and may contribute to autonomous aldosterone production and adrenal hyperplasia in a subgroup of patients with primary aldosteronism.